ALK boss on surprising bottom line: "The underlying operations are getting better and better"

Carste Hellmann, CEO of ALK, is excited about the company's financial report, where earnings in particular were a positive surprise. The difference between deficit and profit depends on how much the company spends on clinical trials from now on, he says.

Carsten Hellmann, CEO of ALK, is proud that the company has delivered 11 percent revenue growth and a better than expected bottom line. Photo: Gregers Tycho / Ritzau / Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles